113 results about "Oxidative injury" patented technology

The invention relates to a freezing liquid for human stem cells and a freezing storage method. Every 1000 ml of the freezing liquid comprises the following components: 20-50 mg of salidroside, 50-100 g of hydroxyethyl modified starch 450 Kd, 10-50 g of carboxylated poly-L-lysine, 50-100 g of sucrose, 20-150 g of trehalose, 5-20 g of antifreeze protein, 5-20 g of glycoprotein, 20-50 ml of DMSO, 60-100 ml of glycerin, and 200-300 ml of fetal calf serum, with the balance being a buffer solution. The freezing liquid for human stem cells is low in dimethyl sulfoxide content, has no side or toxic effect on frozen cells, can effectively keep the activity of stem cells, prevents oxidative injury, and is high in cell thawing rate.

A method of treating and/or preventing oxidative damage, comprising administering an effective IsoK/NeuroK adduct formation suppressing amount of a phenolic amine compound and/or pyridoxamine or pyridoxamine analog, including embodiments where the phenolic compound is at least one of a pyridoxamine, salicylamine, tyrosine compound or an analog thereof.

The invention relates to the technical field of medicinal preparations. Bendamustine hydrochloride is easy to degrade in the preparation process, so in order to prevent degradation products from generating, the aqueous solution of tertiary butanol with certain concentration is used as a solvent; therefore, medicaments and relevant auxiliary materials are dissolved, and the dissolved mixture is subjected to freeze-drying so as to obtain the bendamustine hydrochloride; however, the tertiary butanol is harmful to human bodies when inhaled or orally taken, the conventional literature indicates that the tertiary butanol can cause the oxidative injury of deoxyribonucleic acid (DNA), and experiments of rats and mice prove that the tertiary butanol has the carcinogenicity. The invention provides a bendamustine hydrochloride freeze-dried powder injection for injection and a preparation method thereof. In the preparation method, an organic solvent and particularly the tertiary butanol are not added in the processes of preparation and freeze-drying, so the safety of production and clinical medication is improved greatly. The bendamustine hydrochloride freeze-dried powder injection for the injection has the high stability and water solubility, has the characteristics of stability, controlled quality, safety and reliability, and particularly does not have organic solvent residues.

The invention discloses new medical application of glycyrrhiza inflata ethanol extract and licochalcone A. The inventor discovers that glycyrrhiza inflata and other medical licorice root have obvious chemical ingredient difference, furthermore systematically researches the glycyrrhiza inflata ethanol extract and the important ingredient licochalcone A therein, and discovers that the glycyrrhiza inflata ethanol extract and the licochalcone A have remarkable activity in protecting oxidized cell injury, tissue injury and acute chemical liver injury. Based on the discovery, the extract and an active compound or pharmaceutically acceptable salt, ester and a solvate, a stereoisomer, tautomer, a prodrug and a mixture thereof can be used for preparing medicaments and health products for treating/preventing oxidative injury and/or acute chemical liver injury.

The invention provides a combination for protecting peroxide injury of myocardium. The combination comprises the following raw materials (parts by weight of each raw material are shown in brackets): coenzyme Q100 (5 to 50), L-carnitine (10 to 500), and octocosanol (10 to 100). The combination can lessen lipid peroxidation of a myocardium cell membrane and improve the activity of antioxidant enzymes such as SOD, GSH-Px and CAT, thereby protecting the peroxide injury of the myocardium and delaying or eliminating sports fatigue.

The invention provides a hypoglycemic peptide with the amino acid sequence ADWGGPLPH shown as SEQ ID NO:1 and further provides a modified peptide of the hypoglycemic peptide. Chemical groups, amino acids, polypeptides, proteins or PEG is connected to an N terminal, a C terminal or intermediate residues of the hypoglycemic peptide. Through the hypoglycemic peptide, glucose absorption of smooth muscle cells under the high-glucose condition can be promoted, the glucose tolerance of diabetic mice can be improved, the blood glucose utilization ability of the mice can be enhanced, serum total cholesterol and total triglycerides are significantly reduced, the SOD level is significantly improved, the MDA level is lowered, the oxidative injury of the livers of the diabetic mice is repaired, inflammatory factors in plasma of the diabetic mice are inhibited, and the hypoglycemic peptide can resist metabolic syndromes and can be used for preparing drugs or health care products for treating and/orpreventing diabetes or hyperlipidemia.

The invention relates to application of Trichosanthes kirilowii, safflower and hemlock parsley extracts for relieving oxidative stress injury to drosophila intestinal tract. The Trichosanthes kirilowii, safflower and hemlock parsley extracts are obtained by a water extraction method, a repairing experiment of the Trichosanthes kirilowii, safflower and hemlock parsley extracts on an oxidative injury model of the drosophila intestinal tract is performed, and the result finds that the Trichosanthes kirilowii, safflower and hemlock parsley extracts have excellent activity on the aspects of resisting oxidation, scavenging free radicals and the like, and can be used to prepare antioxidative medicaments, in particular medicaments resisting oxidative injury to the intestinal tract.

The present invention relates to methods for detecting a oxidative stress in a biological sample, methods of determining a cumulative record of oxidative injury, and methods of diagnosing diseases of aging, such as cardiovascular diseases, based on the presence or absence of a biomarker or a component thereof. The present invention also relates to a kit for detecting oxidative stress in a biological sample comprising a stabilizing reactant and an antibody. In some embodiments of the invention, the biomarker of oxidative stress is selected from an aldehyde-protein adduct and an aldehyde metabolite-protein adduct, and the proposed method further comprises measuring separately for the same protein biomarkers of oxydative stress formed with different amino acids of the protein.

The invention discloses a method for treating a disorder or a disease induced by an oxidative stress injury, including administering VEGF-B to a subject; and, a chemical containing VEGF-B protein, VEGF-B expressing plasmids, VEGF-B expressing viruses and/or VEGF-B expressing cells as active ingredients for treating a disorder or a disease induced by an oxidative stress injury. VEGF-B is a strong antioxidant having an intense anti-oxidative effect and capable of up-regulating antioxidant genes and down-regulating oxidant genes, and thus rescuing cellular and vascular degeneration under a pathologic condition. VEGF-B is the first member from the VEGF family to be recognized as a regulatory factor of anti-oxidation pathway, and therefore it can be used as a new medicament for anti-aging and anti-tumor purposes, and for treating varieties of degenerative and oxidative stress injury-related diseases.

The invention provides a garlic saponin liposome, comprising the following components in parts by weight: 1 part of garlic saponin, 10-100 parts of phospholipid, 1-50 parts of cholesterol and 0-50 parts of emulsifier, wherein the garlic saponin liposome can be prepared by such conventional methods as film dispersion method, ultrasonic dispersion method and reverse evaporation method, for example, injection method, freeze drying method, etc. The garlic saponin liposome can be prepared to a plurality of formulations, for example, tablet, capsule, oral liquid, injection, aerosol or drop and the like, and the garlic saponin liposome is applied to preparation of drugs for preventing bacteria, reducing cholesterol, reducing blood fat, preventing platelet aggregation, improving fibrinolytic activity, preventing hypoxia and preventing oxidative damage, etc.

The invention relates to the field of natural medicines, and particularly relates to use of beta-elemene and derivatives thereof in preventing atherosclerosis, and in particular relates to an application in preparation of medicines for treating atherosclerosis. Test results show that beta-elemene and derivatives can remarkably reduce the atherosclerotic plaque area in the coronary artery of an animal model, and meanwhile has remarkable improving effect on two key links in development process of atherosclerosis: adhesion of leukocyte and endothelial cells and peroxidation of lipids. Expression of adherence factors closely related to atherosclerosis can be reduced, so that peroxidation damage of endothelial cells in vitro and in vivo caused by high fat and H2O2 is avoided.

The invention discloses an application of tribulus terrestris in preparation of medicines for preventing and treating retinal injury diseases. The application disclosed by the invention has the beneficial effects that an anti-apoptotic effect of the tribulus terrestris on retinal pigment epithelial cells injured oxidatively and the molecular action mechanism of the tribulus terrestris are discussed by observing the protective effect of the tribulus terrestris on the retinal pigment epithelial cells induced by hydrogen peroxide (H2O2) and injured by oxidative stress and observing the expressionchange of the tribulus terrestris on the retinal pigment epithelial cells treated by H2O2 and cell-apoptosis related molecules so as to provide theoretical basis for utilizing the tribulus terrestristo prevent and treat eye diseases related to injury of the retinal pigment epithelial cells in future.

Disclosed is a method for alleviating the oxidative impairment of vascular function by inhibiting the activity of xanthine oxidase, or active forms thereof. Xanthine oxidase levels have been shown to be increased by a variety of conditions, including sickle cell disease. In the present disclosure, allopurinol is used to inhibit xanthine oxidase activity. As a result of the inhibition of xanthine oxidase, .NO levels in a subject can be maintained. In addition to sickle cell disease, allopurinol inhibition of xanthine oxidase may be used to treat other conditions, including, but not limited to, respiratory distress, kidney disease, liver disease, ischemia-reperfusion injury, organ transplant, sepsis, burns, viral infections and hemorrhagic shock.

The invention provides application of cistanche total glycosides and echinacoside in preparation of medicines for preventing and treating alcoholic liver injury with intestinal injury and regulating intestinal flora. Pharmacological experiment results show that in an alcoholic liver injury mouse model, the cistanche total glycosides and echinacoside can relieve mouse liver tissue morphological injury, reduce mouse liver lipid deposition, reduce the content of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse liver, relieve oxidative injury of mouse liver, and reduce damage of harmful substances such as endotoxin and the like to liver; and meanwhile, the mouse small intestine tissue form damage can be relieved, the intestinal wall villus integrity is improved, and the intestinal flora disorder is regulated. Therefore, the invention has the prospect of being developed into a medicine capable of simultaneously protecting the alcoholic liver injury and the alcoholic intestinal injury, and has important clinical significance and commercial value.

The invention relates to an application of a pyrazine compound in preparation of drugs. The drugs can be used for treating neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis, progressive lateral sclerosis, Friedreich's ataxia, neuropathic pain or glaucoma, inflammation, oxidative damage, and mitochondrial-related diseases.

The invention relates to a nano-drug for preventing or treating cerebral ischemia-reperfusion injury as well as a preparation method and application of the nano-drug. Cerebral ischemia is a cerebrovascular disease which has the greatest threat to human beings, and oxidative injury, inflammatory response and subsequent excitotoxic cell death can be caused by reperfusion as soon as possible. According to the nano-drug, dopamine is oxidized under an alkaline condition to form dopamine quinone, the dopamine quinone is further oxidized to form polydopamine nanoparticles with supramolecular structures, the formed particles are smooth and round in surface, good in sphericity degree and uniform in particle size distribution, a good dispersion state is kept in a solution, and through in-vitro and in-vivo experiments, the polydopamine nanoparticles prove the biological safety. Application of the polydopamine nanoparticles to a cerebral ischemia model shows that the polydopamine nanoparticles canrelieve cerebral ischemia-reperfusion injury, inhibit inflammatory reaction, inhibit activation of an NF-kappa B signal channel and inhibit excessive activation of microglial cells, and have the potential of inhibiting cerebral inflammatory reaction and relieving cerebral ischemia-reperfusion injury.

The invention discloses application of a chitosan oligosaccharide (COSM) with the molecular weight not higher than 3000 to preparing a drug-induced liver injury protecting and treating composition, particularly a composition for protecting and treating acetaminophen-induced liver injury. The invention also discloses a drug-induced liver injury protecting and treating method. The drug-induced liverinjury protecting and treating method comprises providing a liver injury patient with an effective quantity of the COSM. Experiments prove that the COSM can adjust acetaminophen-induced abnormity ofliver function biochemical indexes, significantly reduce abnormal rise of ALT (alanine transaminase) and AST (aspartate transaminase) in mice serum, improve acetaminophen-induced liver injury, improvethe content of a detoxicant of glutathione (GSH) in acetaminophen-induced liver injury-affected liver tissues, enhance the oxidation resistance of acetaminophen-induced oxidative injury-affected liver and reduce the content of malondialdehyde (MDA) of acetaminophen-induced liver oxidative injury. The COSM is expected to be developed and applied to treating liver injury caused by clinical treatment drugs and provide a better choice for patients.

The invention relates to a mitochondria-targeting BODIPY compound and a preparation method and application of liposome-coated nanoparticles of the BODIPY compound. The BODIPY compound contains a cationic group which is easily combined with a mitochondrial membrane with negative electricity in cells, so that the BODIPY compound is targeted to mitochondrial organelles of the cells. The BODIPY compound is wrapped by liposome, and liposome nanoparticles with uniform particle size are prepared in an aqueous solution. The nanoparticles have high stability and good biocompatibility in an aqueous solution. After the nanoparticles are taken by tumor cells, the liposome structure is destroyed, and the released BODIPY compound is targeted to cell mitochondria. Besides, under the 665nm illumination condition, active oxygen generated by the BODIPY compound causes oxidative damage to active molecules in mitochondria, so that tumor cells are killed. The liposome nanoparticles can be applied to tumorphotodynamic therapy as a drug for delivering various photosensitizers.

The invention discloses methods for preparing and producing cigarettes with angelica keiskei. The cigarettes comprise 50 kilograms of tobacco shreds, 5 kilograms of angelica keiskei, 5 kilograms of herba portulacae, 1 kilogram of lavandula officinalis and 5 kilograms of fructus momordicae. The method for producing the cigarettes includes extracting medicine liquid; spraying the medicine liquid in the tobacco shreds; storing and fermenting the tobacco shreds; allowing the medicine liquid to be sufficiently absorbed by the tobacco shreds, drying the tobacco shreds and then winding cigarettes to obtain finished products. The methods have the advantages that selected raw materials contain anti-active oxygen [the anti-active oxygen includes hydroxyl free radicals, superoxide free radicals and hydrogen peroxide, oxygen activity can be generated in cells or tissues in normal life metabolic procedures, and different types of tumor, atherosclerosis, diabetes mellitus, liver injury and the like can be caused by environmental factors such as generation of smoking inductive oxygen, oxidative injury of intracellular lipid, proteins, DNA (deoxyribonucleic acid) and the like and induced oxidative stress], have antitumor activity, antioxidant activity, anti-inflammatory activity and antibacterial activity and are anti-HIV (human immunodeficiency virus) and anti-ulcer, accordingly, swollen sore throats, cough, faucitis and trachitis due to excessive smoking addition can be prevented and treated, respiratory tract mechanisms can be maintained, nose and throat mucitis can be treated, residual harmful substances in lungs can be removed, and active cells and the like of blood can be purified; tar can be effectively reduced, harm can be effectively lessened, and immune functions of the bodies of smokers can be improved.